Thermo Fisher Scientific Inc. $TMO Shares Acquired by Canoe Financial LP

Key Points

• Canoe Financial LP increased its stake in Thermo Fisher Scientific Inc. by 12.5% during the 2nd quarter, acquiring an additional 1,000 shares, bringing its total holdings to 9,000 shares valued at approximately $3.65 million.
• Institutional investors now own 89.23% of the company, with varied activity reported from other firms, including significant percentage increases in holdings by Triangle Securities Wealth Management and Sky Investment Group during the same quarter.
• Thermo Fisher Scientific reported a strong quarterly performance, exceeding EPS expectations with $5.36 earnings per share, and also announced a quarterly dividend of $0.43 per share to be paid on October 15th.

Canoe Financial LP grew its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 12.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 9,000 shares of the medical research company's stock after buying an additional 1,000 shares during the period. Canoe Financial LP's holdings in Thermo Fisher Scientific were worth $3,649,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. GAMMA Investing LLC lifted its position in Thermo Fisher Scientific by 60,610.9% in the 1st quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company's stock valued at $1,203,859,000 after acquiring an additional 2,415,346 shares in the last quarter. Nuveen LLC purchased a new stake in Thermo Fisher Scientific in the 1st quarter valued at about $532,360,000. Sarasin & Partners LLP purchased a new position in shares of Thermo Fisher Scientific in the 1st quarter worth approximately $242,991,000. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in Thermo Fisher Scientific during the fourth quarter worth $195,049,000. Finally, EdgePoint Investment Group Inc. purchased a new position in Thermo Fisher Scientific in the first quarter worth $172,139,000. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Stock Down 0.2%

Shares of NYSE:TMO traded down $1.08 during trading on Friday, hitting $480.02. The stock had a trading volume of 4,241,401 shares, compared to its average volume of 1,433,914. The firm's fifty day moving average is $472.01 and its 200 day moving average is $449.50. The company has a market capitalization of $181.26 billion, a PE ratio of 27.76, a PEG ratio of 2.56 and a beta of 0.75. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $623.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to analysts' expectations of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm's quarterly revenue was up 2.9% on a year-over-year basis. During the same period in the prior year, the firm posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 9.95%.

Insider Buying and Selling

In other news, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the sale, the chief accounting officer owned 2,319 shares in the company, valued at $1,142,408.97. This trade represents a 14.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 30,066 shares of company stock worth $14,182,963 in the last 90 days. 0.33% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on TMO. Scotiabank raised Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price target on the stock in a research report on Friday, July 11th. Wall Street Zen lowered Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research note on Sunday, September 7th. UBS Group raised their price objective on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a report on Thursday, July 24th. Barclays raised Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and raised their price objective for the company from $490.00 to $550.00 in a research note on Thursday, September 11th. Finally, Evercore ISI reduced their price target on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research report on Tuesday, July 8th. Sixteen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $588.35.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.